inpellis Overview

  • Founded
  • 2012
Founded
  • Status
  • Out of Business
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Out of Business

inpellis General Information

Description

Operator of a pharmaceutical company to develop trans-dermal product candidates for treating acute and chronic pain. The company' services focus on providing trans-dermal drugs by developing and applying novel technological advances for musculoskeletal disorders and peripheral neuropathy through biophysical modulation, enabling medical researchers to find an alternative to deliver and consume FDA-approved drugs for treating chronic pain resulting from musculoskeletal disorders and peripheral neuropathy.

Contact Information

Formerly Known As
Alterix
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Primary Office
  • 30 Washington Avenue
  • Suite F
  • Haddonfield, NJ 08033
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

inpellis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-May-2016 00.000 Completed Out of Business
2. IPO 18-Mar-2016 0000 Cancelled Clinical Trials - Phase 1
1. Convertible Debt 01-Sep-2015 $4.25M $4.25M Completed Startup
To view inpellis’s complete valuation and funding history, request access »

inpellis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a pharmaceutical company to develop trans-dermal product candidates for treating acute and chronic pain. The
Pharmaceuticals
Haddonfield, NJ
6 As of 2015
00.000
00000000 00 00.000

0000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000 00000000
Prague, Czech Republic
0000 As of 0000
00000
000000000 00000

00000 00

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in
000000000000000
Bridgewater, NJ
0000 As of 0000
00000
000 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

inpellis Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Zentiva Private Equity-Backed Prague, Czech Republic 0000 00000 000000000 00000
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0
00000000 000000 Formerly VC-backed Vienna, Austria 0 00.000 000000&0 00.000
0000000 Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0000000000 0000000 Venture Capital-Backed Boston, MA 00 00000 00000000
You’re viewing 5 of 31 competitors. Get the full list »

inpellis Executive Team (3)

Name Title Board Seat Contact Info
Patrick Mooney MD Chief Executive Officer & Board Member
David Staskin MD President, Secretary & Board Member
Frank Manguso Chief Financial Officer,Treasurer & Board Member
To view inpellis’s complete executive team members history, request access »

inpellis Board Members (7)

Name Representing Role Since
David Staskin MD inpellis President, Secretary & Board Member 000 0000
Frank Manguso inpellis Chief Financial Officer,Treasurer & Board Member 000 0000
Frederic de Bure inpellis Board Member 000 0000
Galen Grayson MD inpellis Board Member 000 0000
Harry McCoy Ph.D inpellis Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

inpellis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial